The case pertains to an Interlocutory Application filed under Section 35(1)(n) of the Insolvency and Bankruptcy Code, 2016, read with Regulation 45(3)(a) of the IBBI (Liquidation Process) Regulations, 2016. The application seeks the closure of the liquidation process for M/s. Osaka Pharmaceuticals Private Limited, the Corporate Debtor, due to its successful sale as a going concern. The Operational Creditor, M/s. Western Pharma, had previously filed an application under Section 9 of the Code for initiating the Corporate Insolvency Resolution Process (CIRP) against the Corporate Debtor, which was admitted on October 10, 2018. Mr. Hiten M. Parikh was appointed as the Interim Resolution Professional (IRP). Subsequently, Mr. Abhishek Nagori replaced him as the Resolution
…M/s. Western Pharma, an Operational Creditor, initiated Corporate Insolvency Resolution Process (CIRP) against M/s. Osaka Pharmaceuticals Private Limited (Corporate Debtor) under Section 9 of the Insolvency and Bankruptcy Code (IBC). The CIRP was admitted on October 10, 2018, and Mr. Hiten M. Parikh was appointed as the Interim Resolution Professional (IRP). Later, Mr. Abhishek Nagori replaced him as the Resolution Professional (RP). The RP filed an IA No. 439 of 2019 under Section 33 of the IBC for liquidation, which was approved on September 30, 2019, appointing the applicant, Abhishek Nagori, as the liquidator. Public announcements were made on October 5, 2019, and a Stakeholders Consultation Committee (SCC) was formed. In the 4th SCC meeting on September 29, 2020,
…Sign in to view the parties.
Corporate Insolvency Resolution Process…
Mr. Hiten M. Parikh…
The case pertains to an Interlocutory Application filed under Section 35(1)(n) of the Insolvency and Bankruptcy Code, 2016, read with Regulation 45(3)(a) of the IBBI (Liquidation Process) Regulations, 2016. The application seeks the closure of the liquidation process for M/s. Osaka Pharmaceuticals Private Limited, the Corporate Debtor, due to its successful sale as a going concern. The Operational Creditor, M/s. Western Pharma, had previously filed an application under Section 9 of the Code for initiating the Corporate Insolvency Resolution Process (CIRP) against the Corporate Debtor, which was admitted on October 10, 2018. Mr. Hiten M. Parikh was appointed as the Interim Resolution Professional (IRP). Subsequently, Mr. Abhishek Nagori replaced him as the Resolution
…M/s. Western Pharma, an Operational Creditor, initiated Corporate Insolvency Resolution Process (CIRP) against M/s. Osaka Pharmaceuticals Private Limited (Corporate Debtor) under Section 9 of the Insolvency and Bankruptcy Code (IBC). The CIRP was admitted on October 10, 2018, and Mr. Hiten M. Parikh was appointed as the Interim Resolution Professional (IRP). Later, Mr. Abhishek Nagori replaced him as the Resolution Professional (RP). The RP filed an IA No. 439 of 2019 under Section 33 of the IBC for liquidation, which was approved on September 30, 2019, appointing the applicant, Abhishek Nagori, as the liquidator. Public announcements were made on October 5, 2019, and a Stakeholders Consultation Committee (SCC) was formed. In the 4th SCC meeting on September 29, 2020,
…Corporate Insolvency Resolution Process…
Mr. Hiten M. Parikh…